• Markets
    • icon
  • Companies
PAA · ASX

Pharmaust Limited (ASX:PAA)

AU$0.22

 0.0 (0.0%)
ASX:Live
06/05/2024 04:10:28 PM
HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

PAA Overview

PAA Health Scores

Short Term

Mean Revision

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Strong

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About PAA

Website

Pharmaust Limited

Telephone

61.8.9202.6814

Address

Suite 116 1 Kyle Way Claremont, Western Australia (WA) 6010

Description

PharmAust Ltd. engages in the business of developing own drug discovery intellectual property for the treatment of different types of cancers, neurological diseases, and viral infections; and providing highly specialized medicinal and synthetic chemistry services on a contract basis to clients. It operates under the Corporate and Research, and Pharmaceutical-Epichem segments. The Corporate and Research segment includes corporate overhead expenses. The Pharmaceutical-Epichem segment provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries. The company was founded on December 2003 and is headquartered in Claremont, Australia.

PAA Price Chart

Key Stats

Market Cap

AU$86.90M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.06 - 0.54

Trade Value (12mth)

AU$37,166.00

1 week

0%

1 month

-41.33%

YTD

100%

1 year

152.87%

All time high

4.73999

Key Fundamentals

EPS 3 yr Growth

321.700%

EBITDA Margin

-116.70%

Operating Cashflow

-$2m

Free Cash Flow Return

-22.90%

ROIC

-90.90%

Interest Coverage

-40.30

Quick Ratio

2.20

Other Data

Shares on Issue (Fully Dilluted)

354m

HALO Sector

Healthcare

Next Company Report Date

N/A

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

PAA Announcements

Latest Announcements

Date Announcements

30 April 24

Appendix 4C & Quarterly Update

×

Appendix 4C & Quarterly Update

23 April 24

Resignation of Dr Michael Thurn & appointment of John Clark

×

Resignation of Dr Michael Thurn & appointment of John Clark

19 April 24

Application for quotation of securities - PAA

×

Application for quotation of securities - PAA

19 April 24

Cleansing Notice

×

Cleansing Notice

18 April 24

PharmAust makes Head of Manufacturing appointment

×

PharmAust makes Head of Manufacturing appointment

10 April 24

Final Ethics Approval for Open-Label MND Extension Study

×

Final Ethics Approval for Open-Label MND Extension Study

05 April 24

Application for quotation of securities - PAA

×

Application for quotation of securities - PAA

05 April 24

Cleansing Notice

×

Cleansing Notice

02 April 24

Pause in Trading

×

Pause in Trading

02 April 24

Trading Halt

×

Trading Halt

02 April 24

Media clarification

×

Media clarification

27 March 24

Application for quotation of securities - PAA

×

Application for quotation of securities - PAA

27 March 24

Cleansing Notice

×

Cleansing Notice

19 March 24

PharmAust to present at NWR Virtual Healthcare Conference

×

PharmAust to present at NWR Virtual Healthcare Conference

14 March 24

Positive clinical data filed with FDA to support ODD request

×

Positive clinical data filed with FDA to support ODD request

14 March 24

Singapore Healthcare Day Presentation

×

Singapore Healthcare Day Presentation

07 March 24

Application for quotation of securities - PAA

×

Application for quotation of securities - PAA

07 March 24

Cleansing Notice

×

Cleansing Notice

29 February 24

Appendix 4D & Half-Year Report

×

Appendix 4D & Half-Year Report

28 February 24

Application for quotation of securities - PAA

×

Application for quotation of securities - PAA

28 February 24

Cleansing Notice

×

Cleansing Notice

27 February 24

Positive Phase 1 MEND Study Top-Line Results

×

Positive Phase 1 MEND Study Top-Line Results

27 February 24

Presentation - Phase 1 Top-Line Results

×

Presentation - Phase 1 Top-Line Results

26 February 24

Trading Halt

×

Trading Halt

26 February 24

Investor webinar - Phase 1 MND Study Top-Line Results

×

Investor webinar - Phase 1 MND Study Top-Line Results

PAA Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.00 -0.01 -0.02 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.00 -0.01 -0.02 Lock Lock Lock
     Growth % Lock Lock Lock Lock 8.7 -28.6 -259.3 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.00 -0.00 -0.01 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock 15.2 -67.8 -17.0 Lock Lock Lock
     Yield % Lock Lock Lock Lock -3.6 -6.2 -6.6 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.03 0.02 0.01 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.02 0.01 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock 1.0 -17.5 -84.9 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 316 317 321 Lock Lock Lock
Basic m Lock Lock Lock Lock 316 317 321 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 2 3 3 Lock Lock Lock
     Growth % Lock Lock Lock Lock -33.0 58.0 -16.5 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 2 3 3 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -1 0 -1 Lock Lock Lock
     Growth % Lock Lock Lock Lock -82.0 71.0 -315.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock -36.0 -6.6 -32.9 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 136 107 133 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -2 -2 -3 Lock Lock Lock
     Growth % Lock Lock Lock Lock -31.4 2.3 -35.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock -116.4 -72.0 -116.7 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -3 -3 -4 Lock Lock Lock
     Growth % Lock Lock Lock Lock -28.5 1.5 -31.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock -130.3 -81.3 -128.3 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -1 -2 -6 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -1 -2 -6 Lock Lock Lock
     Growth % Lock Lock Lock Lock 1.8 -27.7 -263.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock -62.5 -50.5 -220.0 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -1 -1 -2 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 1 1 2 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -1 -1 -2 Lock Lock Lock
     Growth % Lock Lock Lock Lock 20.0 -32.3 -16.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock -0.5 -0.4 -0.6 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 3 2 3 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 11 10 6 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 1 1 1 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -2 -1 -2 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 2 2 2 Lock Lock Lock
Equity $m Lock Lock Lock Lock 9 8 4 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 10 9 5 Lock Lock Lock
     Growth % Lock Lock Lock Lock 3.8 -11.3 -46.2 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -12.2 -16.9 -101.3 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -15.1 -21.8 -159.7 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -27.7 -28.4 -51.1 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -13.6 -18.1 -90.9 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -9.5 -14.1 -22.9 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -31.5 -27.5 -40.3 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.7 0.4 0.5 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -19.7 -13.2 -42.7 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 4.8 3.2 2.2 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 3.7 2.3 2.2 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 69.4 64.9 89.7 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -102.9 -114.3 -116.1 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 7.5 14.5 13.5 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 3.1 3.5 7.2 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.6 1.3 1.7 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 26.1 17.9 32.8 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.2 0.3 0.5 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.2 0.3 0.5 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -62.5 -50.5 -220.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -12.2 -16.9 -101.3 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -12.2 -16.9 -101.3 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.2 1.3 1.6 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -15.1 -21.8 -159.7 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -15.1 -21.8 -159.7 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 116.9 103.8 50.7 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 48.8 25.1 27.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 165.7 129.0 77.7 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 66.5 58.3 103.0 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 99.2 70.7 -25.3 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

PAA Shortsell

Frequently Asked Questions

The current share price of Pharmaust Limited (PAA:ASX) is AU$0.22.
The 52-week high share price for Pharmaust Limited (PAA:ASX) is AU$0.54.
The 52-week low share price for Pharmaust Limited (PAA:ASX)? is AU$0.06.
Pharmaust Limited (PAA:ASX) does not pay a dividend.
Pharmaust Limited (PAA:ASX) does not pay a dividend.
Pharmaust Limited (PAA:ASX) has a franking level of 0%.
Pharmaust Limited (PAA:ASX) is classified in the Healthcare.
The current P/E ratio for Pharmaust Limited (PAA:ASX) is .
halo-logo-inverted-rgb@72ppi-1
Login
Products
Company
Important

Get the latest insights and hot tips delivered right to your inbox

Apple Store
Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.